Plasma Autoantibodies against Heat Shock Protein 70, Enolase 1 and Ribonuclease/Angiogenin Inhibitor 1 as Potential Biomarkers for Cholangiocarcinoma

Rucksaken, Rucksak; Pairojkul, Chawalit; Pinlaor, Porntip; Khuntikeo, Narong; Roytrakul, Sittiruk; Selmi, Carlo; Pinlaor, Somchai

doi:10.1371/journal.pone.0103259

Cited by 23 publications

(25 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[5][6][7] Recent work showed that ENO1 also played pivotal roles in tumorigenesis. Increased ENO1 expression has been detected in several types of tumor tissues such as Non-Hodgkin's lymphomas, 4 breast cancer, 8 glioma, 9 cholangiocarcinoma, 10 and head and neck cancer. 11 ENO1 overexpression is positively associated with accelerated disease progression and poorer prognosis in most of the aforementioned tumors indicating an oncogenic role of ENO1.…”

mentioning

confidence: 99%

α‐enolase promotes tumorigenesis and metastasis via regulating AMPK/mTOR pathway in colorectal cancer

Zhan

Zhao

Hua

et al. 2017

Molecular Carcinogenesis

View full text Add to dashboard Cite

The α-enolase (ENO1) plays pivotal roles in several types of cancer, but its clinical significance, functional role, and possible mechanism in colorectal cancer (CRC) have remained unclear. Expression level of ENO1 in CRC tissues was examined by qRT-PCR, Western blot, and immunohistochemistry. The effects of ENO1 on cell growth were investigated by MTT, colony formation, flow cytometry assays, and in vivo tumorigenic capacity analysis. The impacts of ENO1 on cell migration and invasion were also explored by scratch-healing, Transwell or Matrigel chamber assays, and in vivo metastatic capacity analysis. Our results showed that the expression level of ENO1 was significantly elevated in CRC tissues. High expression level of ENO1 was associated with disease progression in CRC patients. Overexpression of ENO1 in HCT116 cell line promoted cell proliferation, migration, and invasion in vitro as well as tumorigenesis and metastasis in vivo. In other hand, ablation of ENO1 in HCT116 cells led to totally reverse effects. Mechanistically, we revealed ENO1 could regulate AMPK/mTOR signaling pathway. AMPK pathway activation or mTOR pathway suppression blocked these ENO1 induced alterations. Together, our results demonstrated that ENO1 is a potent promoter of CRC genesis and metastasis at least in part though regulating AMPK/mTOR pathway. These findings also suggested that ENO1 may be a promising therapeutic target in CRC patients.

show abstract

mentioning

confidence: 99%

α‐enolase promotes tumorigenesis and metastasis via regulating AMPK/mTOR pathway in colorectal cancer

Zhan

Zhao

Hua

et al. 2017

Molecular Carcinogenesis

View full text Add to dashboard Cite

show abstract

“…However, these factors were not identified in the present study. The differentially expressed proteins identified in this study were described as antigenic, and among the evaluated proteins, ENO1 and enhancer of polycomb homolog 1 (EPC1) have been previously described as antigenic (22,23). ENO1 is a multifunctional enzyme that has functions in various processes, in addition to its role in glycolysis (24).…”

Section: Discussionmentioning

confidence: 82%

“…ENO1 is a multifunctional enzyme that has functions in various processes, in addition to its role in glycolysis (24). Increased levels of ENO1 autoantibody have been observed in the serum of patients with rheumatoid arthritis and cholangiocarcinoma (22,25). A previous proteomics study identified sputum ENO1 as a potential biomarker to aid in the diagnosis of early-stage lung cancer (26).…”

Section: Discussionmentioning

confidence: 99%

Use of immunoproteomics to identify immunogenic proteins in a rat model of acute respiratory distress syndrome

Liu

Fang

et al. 2017

Molecular Medicine Reports

View full text Add to dashboard Cite

Acute respiratory distress syndrome (ARDS) is a common and life‑threatening clinical syndrome, and seeking biomarkers of ARDS has been an area of continuing research. The present study hypothesized that alterations to certain immunogenic substances occur in injured lungs and are able to specifically bind with corresponding proteins in the blood, and that these proteins may be readily detected. To investigate this hypothesis, a rat model of ARDS was established by cecal ligation and puncture surgery, and an immunoproteomics approach, using serum as the primary antibody in a western blot analysis, was used with the aim of identifying immunogenic proteins in the injured lungs. Ingenuity Pathway Analysis (IPA) was used for bioinformatics analysis, and mass spectrometric analysis was used to identify a total of 38 differentially expressed immunogenic proteins. Bioinformatics analysis revealed that the top canonical pathways in which the identified proteins may be involved were gluconeogenesis I, glycolysis I, choline degradation I, NADH repair and heme degradation. IPA Biomarker Filter analysis with the terms 'acute respiratory distress syndrome/acute lung injury' was used to screen 13 proteins as candidate biomarkers. These proteins were described as antigens, and suggested that paired antibodies may be detected in the plasma of patients at high risk of ARDS. Analysis of these identified proteins may provide novel insights into the potential pathological mechanisms of ARDS.

show abstract

“…Patel et al (12) suggested that the addition of serum CA19-9 may aid in the differentiation of CC in patients with PSC and CC not associated with PSC. Including the proteomic-based autoantibodies analysis against heat shock protein 70, enolase 1 and ribonuclease/angiogenin Inhibitor 1 as diagnostic markers may increase the sensitivity and specificity in the early detection of CC (92,93). Similarly, using matrix-assisted laser desorption/ionization-imaging mass spectrometry (MALDI IMS) to reveal tissue heterogeneity in hepatic CC may aid in revealing novel relevant biomarkers for CC.…”

Section: Diagnostic Developmentmentioning

confidence: 99%

The promising role of epigenetic mediators and microRNAs in the early diagnosis of cholangiocarcinoma (Review)

2019

View full text Add to dashboard Cite

Cholangiocarcinoma (CC) is a highly lethal malignant tumor which arises from the biliary tract epithelium and is notoriously difficult to diagnose. Common risk factors for CC are primary sclerosing cholangitis, liver fluke infestation and hepatolithiasis. Although CCs are relatively uncommon tumors, the worldwide rising incidences and mortality rate for intrahepatic CC (ICC) renders it a disease of interest for research. CCs are usually fatal due to the typically late clinical presentation and the lack of effective non-surgical therapeutic modalities. The overall survival rate, including following tumor resection, is poor with <5% of patients surviving 5 years and this rate has not significantly improved over the past 30 years. Thus, there is a need to diagnose CC at an early stage, and advances in immunohistochemistry, molecular genetics, pharmacogenomics and personalized medicine may aid in the study of the pathological basis of CC at the gene and protein level. Understanding the genetic and proteomic alterations in CC would not only increase the therapeutic efficacy, but would also provide a better treatment strategy. Epigenetic alterations that induce gene expression in cancers have been well established. Among the epigenetic mechanisms, targeting DNA hypermethylation and histone deacetylation with DNA methyltransferase (DNMT) and histone deacetylase (HDAC) inhibitors has been reported in a number of cancer types. In CC, targeting the epigenetic pathways appears to be a promising approach for treatment. This review aims to provide a comprehensive overview of the putative role of epigenetic alterations and proteomic alterations in CC. Furthermore, the role of these alterations in early diagnosis, as prognostic markers, and therapeutics for better treatment strategies will be highlighted. Contents 1. Introduction 2. Diagnostic snags 3. Mechanism of tumorigenesis 4. Epigenetic alterations in cholangiocarcinoma 5. Diagnostic development 6. Epigenetic therapy of cancer 7. Conclusions

show abstract

Plasma Autoantibodies against Heat Shock Protein 70, Enolase 1 and Ribonuclease/Angiogenin Inhibitor 1 as Potential Biomarkers for Cholangiocarcinoma

Cited by 23 publications

References 46 publications

α‐enolase promotes tumorigenesis and metastasis via regulating AMPK/mTOR pathway in colorectal cancer

α‐enolase promotes tumorigenesis and metastasis via regulating AMPK/mTOR pathway in colorectal cancer

Use of immunoproteomics to identify immunogenic proteins in a rat model of acute respiratory distress syndrome

The promising role of epigenetic mediators and microRNAs in the early diagnosis of cholangiocarcinoma (Review)

Contact Info

Product

Resources

About